Experimental vaccine shows promise against dangerous intestinal illness
New Vaccine Technology for E. coli Diarrhea Licensed to Valneva
Researchers from Norway have secured a partnership with a French vaccine company to push forward a promising new approach against a common cause of severe diarrhea.
Scientists at the University of Bergen and the Norwegian Research Center (NORCE) have engineered a novel platform that targets the toxin produced by enterotoxigenic Escherichia coli (ETEC). The bacterium is responsible for millions of cases of diarrheal disease worldwide each year, with the most severe outbreaks occurring in children in low‑ and middle‑income countries.
In a recent development, the technology has been licensed to Valneva, a French vaccine manufacturer, for further preclinical and clinical work. The agreement is a milestone in a decades‑long effort to create a broadly effective ETEC vaccine, which has proven elusive in the past due to the diversity of the bacterial strains and the difficulty of neutralizing its toxin.
“The approach does look promising in the sense that the proteins elicit strong antibody responses that appear to offer protection against diarrheal illness after the first infection in children in developing countries,” said James Fleckenstein, MD, a professor of medicine and molecular microbiology at Washington University School of Medicine in St. Louis. He added, “We still have a lot of work to do to translate these findings to an actual vaccine.”
The technology is still in the research phase and has not yet been tested as an approved vaccine among the public. The licensing deal allows Valneva to conduct additional laboratory studies, clinical trials, and regulatory reviews before a potential product can reach patients. The research team noted that more work remains to establish safety, efficacy, and manufacturing feasibility.
ETEC remains one of the most common bacterial causes of severe diarrhea worldwide, and it continues to disproportionately affect young children. “If the vaccine eventually reaches patients, researchers hope it could help protect children against some of the most severe forms of diarrheal disease caused by ETEC,” said Dr. Fleckenstein.
In the meantime, experts advise travelers to take practical steps to reduce their risk of infection. Fleckenstein recommends avoiding high‑risk foods, such as street‑vendor meals in areas where sanitation is poor, drinking bottled water in higher‑risk regions, and maintaining good hand hygiene. He also noted that vaccines are available to protect against typhoid fever, and travelers should consult a physician before international travel.
While the new technology represents a significant advance, it is still early in its development. The next phases of research will determine whether it can ultimately become the first effective vaccine against one of the world’s leading causes of severe digestive illness.
